Strategic financing Recent Series A and expansion financing totaling at least $18 million suggests validated investor confidence and available runway to pursue partnerships or licensing deals, presenting an opportunity for BD outreach to potential acquirers or co-development partners.

Acquisition potential Optioned right for Janssen to acquire VPI after Phase 2 trial creates a window for strategic collaborations, licensing discussions, or milestone-driven partnerships with big pharma seeking early access to a first-in-class mAb targeting the IGF-I/αVβ3 axis.

Clinical progress Lead program VPI-2690B is moving into Phase 2 for diabetic nephropathy, signaling near-term data opportunities for risk-sharing deals, collaboration on biomarkers, or co-development discussions with companies focused on diabetic kidney disease.

Diabetes focus Targeted mechanism involves IGF-I/αVβ3 signaling and podocyte/endothelial cell pathways; potential sales angle with diabetes care platforms, nephrology patient populations, and services looking to expand their nephroprotection or kidney disease portfolios.

Global exposure Company operates with UNC-CH IP, notable venture backing, and a public-facing site with a modern tech stack; offer opportunities for regional licensing, companion diagnostic collaborations, or academic-industry co-development programs to accelerate timelines.